| Trade Names: | |
| Synonyms: | |
| Status: | Approved (2018) |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| ATC: | L02BB05 |
| UNII: | 4T36H88UA7 |
| InChI Key | HJBWBFZLDZWPHF-UHFFFAOYSA-N |
|---|---|
| Smile | |
| InChI |
|
| Property Name | Value |
|---|---|
| Molecular Formula | C21H15F4N5O2S |
| Molecular Weight | 477.44 |
| AlogP | 3.53 |
| Hydrogen Bond Acceptor | 5.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 3.0 |
| Polar Surface Area | 89.33 |
| Molecular species | NEUTRAL |
| Aromatic Rings | 2.0 |
| Heavy Atoms | 33.0 |
| Primary Target | |
|---|---|
| Androgen receptor |
| Targets | EC50(nM) | IC50(nM) | Kd(nM) | Ki(nM) | Inhibition(%) | |
|---|---|---|---|---|---|---|
|
Transcription factor
Nuclear receptor
Nuclear hormone receptor subfamily 3
Nuclear hormone receptor subfamily 3 group C
Nuclear hormone receptor subfamily 3 group C member 4
|
- | 16-200 | - | 35-1452 | - |
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Prostatic Neoplasms | 4 | D011471 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 4 | D064129 | ClinicalTrials |
| Prostatic Neoplasms | 4 | D011471 | ClinicalTrials |
| Prostatic Neoplasms | 4 | D011471 | ClinicalTrials |
| Prostatic Neoplasms, Castration-Resistant | 4 | D064129 | FDA |
| Salivary Gland Neoplasms | 2 | D012468 | ClinicalTrials |
| Liver Diseases | 1 | D008107 | ClinicalTrials |
| Resources | Reference |
|---|---|
| CAS NUMBER | 956104-40-8 |
| ChEMBL | CHEMBL3183409 |
| DrugBank | DB11901 |
| DrugCentral | 5278 |
| EPA CompTox | DTXSID40241899 |
| FDA SRS | 4T36H88UA7 |
| Guide to Pharmacology | 9043 |
| PubChem | 24872560 |
| SureChEMBL | SCHEMBL909297 |
| ZINC | ZINC000043174901 |